93 research outputs found
Integrative Systems Approaches Towards Brain Pharmacology and Polypharmacology
Polypharmacology is considered as the future of drug discovery and emerges as the next paradigm of drug discovery. The traditional drug design is primarily based on a “one target-one drug” paradigm. In polypharmacology, drug molecules always interact with multiple targets, and therefore it imposes new challenges in developing and designing new and effective drugs that are less toxic by eliminating the unexpected drug-target interactions. Although still in its infancy, the use of polypharmacology ideas appears to already have a remarkable impact on modern drug development. The current thesis is a detailed study on various pharmacology approaches at systems level to understand polypharmacology in complex brain and neurodegnerative disorders. The research work in this thesis focuses on the design and construction of a dedicated knowledge base for human brain pharmacology. This pharmacology knowledge base, referred to as the Human Brain Pharmacome (HBP) is a unique and comprehensive resource that aggregates data and knowledge around current drug treatments that are available for major brain and neurodegenerative disorders. The HBP knowledge base provides data at a single place for building models and supporting hypotheses. The HBP also incorporates new data obtained from similarity computations over drugs and proteins structures, which was analyzed from various aspects including network pharmacology and application of in-silico computational methods for the discovery of novel multi-target drug candidates. Computational tools and machine learning models were developed to characterize protein targets for their polypharmacological profiles and to distinguish indications specific or target specific drugs from other drugs. Systems pharmacology approaches towards drug property predictions provided a highly enriched compound library that was virtually screened against an array of network pharmacology based derived protein targets by combined docking and molecular dynamics simulation workflows. The developed approaches in this work resulted in the identification of novel multi-target drug candidates that are backed up by existing experimental knowledge, and propose repositioning of existing drugs, that are undergoing further experimental validations
IN SILICO METHODS FOR DRUG DESIGN AND DISCOVERY
Computer-aided drug design (CADD) methodologies are playing an ever-increasing role in drug discovery that are critical in the cost-effective identification of promising drug candidates. These computational methods are relevant in limiting the use of animal models in pharmacological research, for aiding the rational design of novel and safe drug candidates, and for repositioning marketed drugs, supporting medicinal chemists and pharmacologists during the drug discovery trajectory.Within this field of research, we launched a Research Topic in Frontiers in Chemistry in March 2019 entitled “In silico Methods for Drug Design and Discovery,” which involved two sections of the journal: Medicinal and Pharmaceutical Chemistry and Theoretical and Computational Chemistry. For the reasons mentioned, this Research Topic attracted the attention of scientists and received a large number of submitted manuscripts. Among them 27 Original Research articles, five Review articles, and two Perspective articles have been published within the Research Topic. The Original Research articles cover most of the topics in CADD, reporting advanced in silico methods in drug discovery, while the Review articles offer a point of view of some computer-driven techniques applied to drug research. Finally, the Perspective articles provide a vision of specific computational approaches with an outlook in the modern era of CADD
Experimental and computational methods for identification of novel fungal histone acetyltransferase Rtt109 inhibitors
University of Minnesota Ph.D. dissertation. February 2014. Major: Medicinal Chemistry. Advisor: Elizabeth A. Amin. 1 computer file (PDF); xii, 180 pages.Rtt109 is a fungal-specific histone acetyltransferase that catalyzes histone H3 lysine 56 acetylation and is a promising antifungal drug target. To identify novel Rtt109 inhibitors as potential drug scaffolds, we employed in vitro high throughput screening (HTS) and various computer-assisted strategies, including molecular dynamics, docking, three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis, pharmacophore modeling, and Support Vector Machine (SVM) mining. An initial experimental screening of 82,861 compounds (HTS1) yielded hits with activity ranging from 0.49 - 17.5 µM against Rtt109. The molecular dynamics simulation of Rtt109 suggested that the histone lysine tunnel, a potential inhibitor binding site, was not flexible and thus the use of a rigid protein structure of Rtt109 was appropriate for docking studies. From a virtual screen using Surflex-Dock, we have identified 878 additional compounds as potential hits, with predicted Kd values of 0.1 nm or lower. Based on preliminary experimental data from HTS1, validated pharmacophore maps were developed and used to pinpoint potential Rtt109 ligand-receptor interactions. 3D-QSAR CoMFA and CoMSIA models that were also derived from the hit series generated in the initial experimental HTS display high self-consistency (r2 = 0.985 [CoMFA] and r2 = 0.976 [CoMSIA]) and robust internal predictivity (rcv2 = 0.754 [CoMFA] and rcv2 = 0.654 [CoMSIA]). Importantly, key features identified in both the pharmacophore hypotheses and the 3D-QSAR models agreed well with each other and with experimentally defined structural features in the Rtt109 lysine-binding tunnel. In addition, our optimized SVM models demonstrated high predictive power against the external test sets for Rtt109 with accuracy of 91.1%. We also identified novel features with significant differentiating ability to separate Rtt109 inhibitors from non-inhibitors
Theoretical-experimental study on protein-ligand interactions based on thermodynamics methods, molecular docking and perturbation models
The current doctoral thesis focuses on understanding the thermodynamic
events of protein-ligand interactions which have been of paramount importance from traditional Medicinal
Chemistry to Nanobiotechnology. Particular attention has been made on the application of state-of-the-art
methodologies to address thermodynamic studies of the protein-ligand interactions by integrating structure-based
molecular docking techniques, classical fractal approaches to solve protein-ligand complementarity problems,
perturbation models to study allosteric signal propagation, predictive nano-quantitative structure-toxicity relationship
models coupled with powerful experimental validation techniques. The contributions provided by this work could
open an unlimited horizon to the fields of Drug-Discovery, Materials Sciences, Molecular Diagnosis, and
Environmental Health Sciences
Study and Design of Kynurenine Aminotransferase-II Inhibitors for the Treatment of Neurological Conditions
The majority of tryptophan metabolism passes through the kynurenine pathway. Metabolic imbalances in this pathway are implicated disease. KYNA, transaminated by the kynurenine aminotransferase (KAT) enzymes, is elevated in patients with schizophrenia. Schizophrenia is a neuropsychiatric disease with limited treatment options and debilitating symptoms. Glutamatergic systems are thought to have a significant role in its pathogenesis, providing a basis by which KYNA, an endogenous glutamate antagonist, is implicated in the disease. Four pyridoxal 5’-phosphate-dependent homologues of KAT are reported. KAT-II is primarily responsible for KYNA production in the human brain. KAT-II inhibitors reduce KYNA production, increase neurotransmitter release and elicit pro-cognitive effects, indicative of their potential as novel therapies in treating schizophrenia. In this work, surface plasmon resonance has been employed to screen a fragment library, from which two fragments, F6037-0164 and F0037-7280 were pursued (IC50 of 524.5 μM and 115.2 μM, respectively). Another strategy was to consider estrogen compounds as schizophrenia is a sexually dimorphic condition, in which female patients have reduced estrogen levels. Enzyme inhibitory assays displayed estradiol disulfate as a strong inhibitor of KAT-I and KAT-II (IC50: 291.5 μM and 26.3 μM, respectively), with estradiol, estradiol 3-sulfate and estrone sulfate inhibiting weakly. Molecular modelling suggests that the 17-sulfate moiety in estradiol disulfate improves its potency by 10-100 fold compared to estradiol. This 17-sulfate moiety was mimicked on existing KAT-II inhibitor scaffolds to develop two novel inhibitors, JN-01 and JN-02, with improved potencies (IC50: 73.8 μM and 112.8 μM, respectively). Co-crystallisation studies resulted in the determination of a human KAT-II crystal structure (PDB ID: 6D0A) with 1.47 Å resolution, the highest resolution structure provided for KAT-II, with the least structural inconsistencies
In Silico Strategies for Prospective Drug Repositionings
The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning—finding new pharmacodynamic properties for already approved drugs—becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug–target and drug–drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions
IN SILICO APPROACHES IN DRUG DESIGN AND DEVELOPMENT: APPLICATIONS TO RATIONAL LIGAND DESIGN AND METABOLISM PREDICTION
In the last decades, the applications of computational methods in medicinal chemistry have experienced significant changes which have incredibly expanded their approaches, and more importantly their objectives. The overall aim of the present research project is to explore the different fields of the modelling studies by using well-known computational methods as well as different and innovative techniques.
Indeed, computational methods traditionally consisted in ligand-based and the structure-based approaches substantially aimed at optimizing the ligand structure in terms of affinity, potency and selectivity. The studies concerning the muscarinic receptors in the present thesis applied these approaches for the rational design of novel improved bioactive molecules, interacting both in the orthosteric (e.g., 1,4-dioxane agonist) and in the allosteric sites. The research includes also the application of a novel method for target optimization, which consists in the generation of the so-called conformational chimeras to explore the flexibility of the modelled GPCR structures.
In parallel, computational methods are finding successful applications in the research phase which precedes the ligand design and which is focused on a detailed validation and characterization of the biological target. A proper example of this kind of studies is given by the study regarding the purinergic receptors, which is aimed at the identification and characterization of potential allosteric binding pockets for the already reported inhibitors, exploiting also innovative approaches for binding site predictions (e.g., PELE, SPILLO-PBSS).
Over time, computational applications felt a rich extension of their objectives and one of the clearest examples is represented by the ever increasing attempts to optimize the ADME/Tox profile of the novel compounds, so reducing the marked attrition in drug discovery caused by unsuitable pharmacokinetic profiles. Coherently, the first and main project of the present thesis regards the field of metabolism prediction and is founded on the meta-analysis and the corresponding database called MetaSar, manually collected from the recent specialized literature. This ongoing extended project includes different studies which are overall aimed at developing a comprehensive method for metabolism prediction. In detail, this Thesis reports an interesting application of the database which exploits an innovative predictive technique, the Proteochemometric modelling (PCM). This approach is indeed at the forefront of the latest modelling techniques, as it perfectly fits the growing request of new solutions to deal with the incredibly huge amount of data recently produced by the \u201comics\u201d disciplines. In this context, MetaSar represents an alternative and still appropriate source of data for PCM studies, which also enables the extension of its fields of application to a new avenue, such as the prediction of metabolism biotransformation. In the present thesis, we present the first example of these applications, which involves the building of a classification model for the prediction of the glucuronidation reaction.
The field of glucuronidation reactions is exhaustively explored also through an homology modelling study aimed at defining the complete three-dimensional structure of the enzyme UGT2B7, the main isoform of glucuronidation enzymes in humans, in complex with the cofactor UDPGA and a typical substrate, such as Naproxen. The paths of the substrate entering to the binding site and the egress of the product have been investigated by performing Steered Molecular Dynamics (SMD) simulations, which were also useful to gain deeper insights regarding the full mechanism of action and the movements of the cofactor
Recommended from our members
Computer-Aided Design of Ligands at Multiple Protein Targets for Multifactorial Diseases
Today, drug discovery predominately focuses on the design of ligands with high selectivity towards a specific biological target. A significant limitation in the case of multi-factorial diseases (e.g. neurodegenerative disorders) is that effective therapy may require multi-target drugs addressing the complexity of multi-factorial pathologies. Here, single- and multi-target ligand design was investigated to discover novel compounds active at multiple proteins/multiple binding sites including allosteric ligands.
Calpain-1, a challenging target, was selected to develop and evaluate computational approaches to the discovery of novel ligands. Current selective calpain-1 inhibitors are reported to bind to an allosteric site and their mode of action has remained elusive. To elucidate this, a structure-based virtual screening protocol was implemented to find chemically novel compounds with improved selectivity and a reduced side-effects profile.
To develop methods for the discovery of multi-target ligands, a multi-target design approach, which could be beneficial in the treatment of Lung Carcinoma and Neurodegenerative diseases, was investigated. A novel ensemble of proteins was targeted to elevate intracellular cAMP, deemed to be beneficial in these diseases resulting in the discovery of ligands with high binding affinity at three targets, PDE10A, A1 and A2A receptors.
In tandem, functional activity at the A2A receptor and PDE10A was investigated, resulting in the discovery of novel compounds, which exhibited anti-proliferative effects in lung carcinoma cell-lines correlating with the co-expression of the two targets and increased cAMP levels. Critically, the dynamics of one amino acid residue, Val84, was identified as a novel conformational descriptor of A2A receptor activation.
Overall, novel single- and multi-target ligand design approaches are presented in this work, which could be applicable to a wide range of ligand design problems, across (multi-factorial) disease areas and target families. The findings may facilitate improved design of allosteric calpain-1 inhibitors using the PEF(S) domain, and encourage investigating the therapeutic benefits of dual ligands at the A2A receptor and PDE10A against lung cancer in vivo.IDB Cambridge International Scholarship and ERC Starting Grant (No. 336159
Cancer and aging: a multidisciplinary medicinal chemistry approach on relevant biological targets such as proteasome, sirtuins and interleukin 6
It is well known that ageing and cancer have common origins due to internal and environmental stress and share some common hallmarks such as genomic instability, epigenetic alteration, aberrant telomeres, inflammation and immune injury. Moreover, ageing is involved in a number of events responsible for carcinogenesis and cancer development at the molecular, cellular, and tissue levels.
Ageing could represent a “blockbuster” market because the target patient group includes potentially every person; at the same time, oncology has become the largest therapeutic area in the pharmaceutical industry in terms of the number of projects, clinical trials and research and development (R&D) spending, but cancer remains one of the leading causes of mortality worldwide.
The overall aim of the work presented in this thesis was the rational design of new compounds able to modulate activity of relevant targets involved in cancer and aging-related pathologies, namely proteasome and immunoproteasome, sirtuins and interleukin 6. These three targets play different roles in human cells, but the modulation of its activity using small molecules could have beneficial effects on one or more aging-related diseases and cancer.
We identified new moderately active and selective non-peptidic compounds able to inhibit the activity of both standard and immunoproteasome, as well as novel and selective scaffolds that would bind and inhibit SIRT6 selectively and can be used to sensitize tumor cells to commonly used anticancer agents such gemcitabine and olaparib. Moreover, our virtual screening approach led us also to the discovery of new putative modulators of SIRT3 with interesting in-vitro and cellular activity.
Although the selectivity and potency of the identified chemical scaffolds are susceptible to be further improved, these compounds can be considered as highly promising leads for the development of future therapeutics
Cholinesterase Research
This collection of 10 papers includes original as well as review articles focused on the cholinesterase structural aspects, drug design and development of novel cholinesterase ligands, but also contains papers focused on the natural compounds and their effect on the cholinergic system and unexplored effects of donepezil
- …